Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC Alzheimer's Claims
Cassava Sciences shares dropped after the company agreed to a $40 million settlement with the Securities and Exchange Commission over charges that it manipulated clinical trial data related to its Alzheimer’s disease drug.
27 Sep 14:10 · Investopedia